Abstract: PO2088
COVID-19 Infection in Kidney Transplant Patients: An Italian One-Year Single-Center Experience
Session Information
- Transplantation: Clinical - Allocation, Evaluation, Prognosis, and Viral Onslaughts
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 1902 Transplantation: Clinical
Authors
- Campise, Mariarosaria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Alfieri, Carlo, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Cresseri, Donata Carmela, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Gandolfo, Maria Teresa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Binda, Valentina, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Regalia, Anna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
- Messa, Piergiorgio, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
Background
COVID-19 is a life-threatening infection among elderly, comorbid patients, or transplanted patients. Lombardy (Region of Italy), accounts for 786.324 cases as of April 21st, 2021.
Methods
We retrospectively describe our single Centre experience in 82 adult kidney-transplant patients with COVID-19 infection during two pandemic outbreaks: 27 (first outbreak) and 65 (second).
Results
Thirty-seven patients were hospitalized (HP) and 65 were home managed (HM). Infection presented with fever (80 %), cough (51 %) and dyspnea (33 %). HP were older (60±11vs 50±14 years, p=0,001), had more severe respiratory symptoms (dyspnea 62.1%, p<0.0001 – cough 67% p=0.008), and a longer length of disease (30±28 vs 21±10, p=0.04). Incidence of acute kidney injury (AKI) was 29.7% (p<0.0001). Steroid dosage was increased in 66% of patients, p=0.0003 while Calcineurin Inhibitors were reduced up to one third in 45% of cases, p<0.0001. Eleven patients died (13%). HM patients recovered completely without sequelae. In the overall cohort, AKI development (p=0.006 OR 50.4 CI 95% 3.0-836) and age (p=0.04 OR 1.1 CI 95% 1.0-1.2) were the most important factors influencing the probability of death during the infection.
Conclusion
Although we report a relatively low incidence of infection (5.1 %) incidence of death is almost four times higher than in general population.
Table 1: patients characteristics before COVID-19 infection.